Skip to main content

[DEK-DKK1-P207] Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Clinical Trial Grant
Duke Scholars

Awarded By

Leap Therapeutics, Inc.

Start Date

November 4, 2022

End Date

November 6, 2027
 

Awarded By

Leap Therapeutics, Inc.

Start Date

November 4, 2022

End Date

November 6, 2027